Aims: Heart failure (HF) following acute myocardial infarction (AMI) is a global health concern, but data on risk factors associated with HF hospitalization post-AMI are limited.
Methods And Results: We analysed data from the Myocardial Ischaemia National Audit Project, including patients admitted with AMI from 1 January 2006 to 31 March 2019. Data linkage with Hospital Episode Statistics Admitted Patient Care and the Office for National Statistics facilitated a longitudinal analysis. High-risk patients were identified using dapagliflozin in patients without diabetes mellitus with acute myocardial infarction (DAPA-MI) and EMPAgliflozin on Hospitalization for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction (EMPACT-MI) criteria. We assessed clinical outcomes, adherence to European Society of Cardiology quality indicators, and predictors of HF-related hospitalizations. Out of 1 046 480 AMI patients, 9.1% overall, 17.2% in the DAPA-MI cohort, and 16.6% in the EMPACT-MI cohort experienced HF hospitalization within a year post-AMI. High-risk patients, defined by the presence of five risk factors, had nearly one in four hospitalizations with HF at 1-year follow-up. The predicted adjusted incidence rate for heart failure within 1 year almost doubled from 64.5 cases per 1000 person-years [95% confidence interval (CI): 51.1 to 78.0] in 2005, to 118.2 cases per 1000 person-years in 2019 (95% CI: 115.0 to 121.5). Heart failure hospitalization was associated with a three-fold increase in 1-year mortality (hazard ratio 3.01, 95% CI 2.95-3.13).
Conclusion: One in 10 AMI patients experienced HF hospitalization within the first-year post-AMI, with rising trends in high-risk subgroups. These findings highlight the need for targeted post-AMI care strategies to improve outcomes and address the increasing burden of HF in the modern percutaneous coronary intervention era.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896973 | PMC |
| http://dx.doi.org/10.1093/ehjopen/oeaf013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Murine Aortic Valve Cell Heterogeneity at Birth.
Arterioscler Thromb Vasc Biol
March 2025
Department of Pediatrics, Division of Pediatric Cardiology, Medical College of Wisconsin, Milwaukee (T.B., J.R.K., A.J.K., J.L.).
Background: Heart valve function requires a highly organized ECM (extracellular matrix) network that provides the necessary biomechanical properties needed to withstand pressure changes during each cardiac cycle. Lay down of the valve ECM begins during embryogenesis and continues throughout postnatal stages when it is remodeled into stratified layers and arranged according to blood flow. Alterations in this process can lead to dysfunction and, if left untreated, heart failure.
View Article and Find Full Text PDFVericiguat in patients with heart failure and implantable cardioverter-defibrillator.
Drugs Context
March 2025
Cardiology Department, Arrhythmia Unit, University Hospital La Paz, Madrid, Spain.
Background: This analysis assesses the effectiveness and tolerability profile of vericiguat in patients with heart failure with reduced ejection fraction (HFrEF) and implantable cardioverter-defibrillator, with an emphasis on the emergence of ventricular arrhythmias.
Methods: Retrospective analysis of patients with HFrEF and implantable cardioverter-defibrillator who started treatment with vericiguat in daily clinical practice in a tertiary university hospital in Spain.
Results: The study population comprised 14 patients treated since January 2023.
15-Year trends, predictors, and outcomes of heart failure hospitalization complicating first acute myocardial infarction in the modern percutaneous coronary intervention era.
Eur Heart J Open
March 2025
Keele Cardiovascular Research Group, School of Medicine, Keele University, ST5 5BG, UK.
Aims: Heart failure (HF) following acute myocardial infarction (AMI) is a global health concern, but data on risk factors associated with HF hospitalization post-AMI are limited.
Methods And Results: We analysed data from the Myocardial Ischaemia National Audit Project, including patients admitted with AMI from 1 January 2006 to 31 March 2019. Data linkage with Hospital Episode Statistics Admitted Patient Care and the Office for National Statistics facilitated a longitudinal analysis.
Diastolic Dysfunction Unveiling Cardiac Light-Chain Amyloidosis: A Case Report.
Med Res Arch
December 2024
Department of Neurology, University Hospital "12 de Octubre", Madrid, Spain.
Background: Cardiac light-chain amyloidosis represents a critical component of this multi-systemic disease, significantly impacting prognosis. The extent of cardiac free light-chain deposition is the primary determinant of survival.
Case Presentation: We report the case of a 67-year-old male with a 10-year history of diabetes mellitus and arterial hypertension who presented with a two-day history of chest discomfort and difficulty lying down or sleeping, along with a two-month history of progressively worsening exertional dyspnea.
Interventional closure of artificial vascular anastomotic fistula after aortic replacement: a case report.
Front Cardiovasc Med
February 2025
Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China.
Two years ago, the patient suffered from type A aortic dissection. As a result, partial aortic dissection artificial vascular replacement and partial aortic arch artificial vascular replacement were performed. Six months after the operation, an anastomotic fistula in the ascending aorta was detected, which subsequently progressed to chronic heart failure of New York Heart Association (NYHA grade) class III.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!